| 摘要 |
Significantly increased removal of immunal complexes and tumor specific antibody generation are achieved by extracorporeal plasma perfusion over a therapeutic immobilized protein A (staphylococcal), SPA. The perfused plasma is returned to the host or can be taken off one person and used to treat another and stored in perfused plasma banks. Immobilized protein A quantities, volumes of plasma perfused and the rate of administration based on clinical and toxicity evaluations are set forth. A non-toxic drug infusion, such as cytosine arabinoside, during the immediate postperfusion period obtains an observed tumoricidal response far exceeding those due to the extracorporeal plasma perfusion or drug infusion alone representing an in vivo synergism between tumor specific antibody and the drug. Also disclosed are the therapeutic protein A cartridge, its loading and delivery system, a miniaturized immunoabsorbent apparatus enabling the processing of serum samples for testing small quanitities of plasma, and a radioimmuno-assay for detecting and measuring tumor specific antibodies in the serum samples for profiling and screening of patients for treatment and assessment. The United States government has rights in these inventions pursuant to U.S. Public Health Service Grants or Awards 5K04AI00302 and 5R01GM23517. |
